ISRCTN39045408已完成不适用
Anti-tumour necrosis factor therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over two years
Karolinska University Hospital (Sweden)0 个研究点目标入组 40 人开始时间: 2010年4月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with early RA (disease duration less than 12 months)
- •2. Participated in the Swefot (SWEdish PHarmacOTherapy) study at Karolinska University Hospital at Huddinge
- •3. Patients started treatment with methotrexate
- •4. Active disease defined as a Disease Activity Score of 28 joints (DAS28) above 3.2
- •5. Aged between 18 and 80 years, either sex
排除标准
- •1. Prior DMARD therapy
- •2. Contraindication to any of the trial medications
研究者
相似试验
招募中
不适用
Impact of anti-tumor necrosis factor antibodies treatment on the semen quality of inflammatory bowel diseases patientsfertilityreproduction10013356NL-OMON33788Erasmus MC, Universitair Medisch Centrum Rotterdam20
进行中（未招募）
不适用
Impact of anti-tumor necrosis factors antibodies treatment on fertility of inflammatory bowel diseases male patientsFertility influenced by antiTNF treatmentMedDRA version: 9.1Level: LLTClassification code 10016469Term: Fertility investigationsEUCTR2008-005619-16-NLErasmus Medical Center
已完成
不适用
Effect of anti-tumour necrosis factor alpha (TNFa) therapy on blood vessel health in patients with rheumatoid arthritisMusculoskeletal DiseasesOther rheumatoid arthritisRheumatoid arthritisISRCTN57761809niversity of Dundee (UK)90
已完成
不适用
Effect of 8 weeks of Pilates exercise and vitamin D on Tumor necrosis factor-a and interleukin-10 levels in overweight meObesity and overweight.Obesity due to excess caloriesE66.0IRCT20190831044650N2Qaemshahr branch, Islamic Azad University56
进行中（未招募）
1 期
To see whether for patients with established rheumatoid arthritis that have already achieved a good response to Tumour Necrosis Factor Inhibitor (TNF inhibitor) treatment, whether the treatment be tapered to a minimum dose without affecting the control of disease activity.EUCTR2010-020738-24-GBKing's College London97